MX2009005447A - Derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona sustituidos, su preparacion y uso de los mismos como ligandos de los receptores cb1 de canabinoides. - Google Patents

Derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona sustituidos, su preparacion y uso de los mismos como ligandos de los receptores cb1 de canabinoides.

Info

Publication number
MX2009005447A
MX2009005447A MX2009005447A MX2009005447A MX2009005447A MX 2009005447 A MX2009005447 A MX 2009005447A MX 2009005447 A MX2009005447 A MX 2009005447A MX 2009005447 A MX2009005447 A MX 2009005447A MX 2009005447 A MX2009005447 A MX 2009005447A
Authority
MX
Mexico
Prior art keywords
substituted
preparation
dfflydro
pyridazin
pyrazolo
Prior art date
Application number
MX2009005447A
Other languages
English (en)
Inventor
Murielle Rinaldi-Carmona
Christian Congy
Didier Van Broeck
Victor Dos Santos
Arnaud Rouquette
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009005447A publication Critical patent/MX2009005447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

La presente invención tiene por objeto compuestos que responden a la fórmula (I), en la cual: -R1 representa: un alquilo (C1-C12) no sustituido o sustituido; un radical carbocíclico no aromático en (C3-C12) no sustituido o sustituido; un fenilo no sustituido o sustituido; un bencilo no sustituido o sustituido; un fenetilo no sustituido o sustituido; un benzhidrilo; un benzhidrilmetilo; un radical heterocíclico aromático; - R2 representa un fenilo no sustituido o sustituido; - R3 representa un fenilo no sustituido o sustituido; - R4 representa un átomo de hidrógeno, un alquilo (C1-C4), un alcoxi (C1-C4), un hidroxi; -Alk representa un alquilo (C1-C4) no sustituido o sustituido. La invención también se refiere a un procedimiento para la preparación y aplicación de ellos en terapéutica, como ligandos de los receptores CB1 de los canabinoides localizados al nivel central y/o periférico.
MX2009005447A 2006-11-23 2007-11-19 Derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona sustituidos, su preparacion y uso de los mismos como ligandos de los receptores cb1 de canabinoides. MX2009005447A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0610371A FR2909090B1 (fr) 2006-11-23 2006-11-23 Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
PCT/FR2007/001889 WO2008068424A2 (fr) 2006-11-23 2007-11-19 Derives de 2, 5-dihydro-3h-pyrazolo [4, 3-c] pyridazin-3-one substitues, leur preparation et leur utilisation comme ligands des recepteurs cb1 des cannabinoides

Publications (1)

Publication Number Publication Date
MX2009005447A true MX2009005447A (es) 2009-08-07

Family

ID=38229329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005447A MX2009005447A (es) 2006-11-23 2007-11-19 Derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona sustituidos, su preparacion y uso de los mismos como ligandos de los receptores cb1 de canabinoides.

Country Status (20)

Country Link
US (1) US7915258B2 (es)
EP (1) EP2094706B1 (es)
JP (1) JP2010510297A (es)
KR (1) KR20090092774A (es)
CN (1) CN101541802A (es)
AR (1) AR063898A1 (es)
AT (1) ATE494290T1 (es)
AU (1) AU2007330652A1 (es)
BR (1) BRPI0719291A2 (es)
CA (1) CA2668196A1 (es)
CL (1) CL2007003346A1 (es)
DE (1) DE602007011815D1 (es)
FR (1) FR2909090B1 (es)
IL (1) IL198523A0 (es)
MX (1) MX2009005447A (es)
PE (1) PE20081496A1 (es)
RU (1) RU2009123841A (es)
TW (1) TW200836739A (es)
UY (1) UY30742A1 (es)
WO (1) WO2008068424A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US20090074717A1 (en) * 2007-07-13 2009-03-19 Martin Robert Leivers Anti-viral compounds, compositions, and methods of use
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
JP5800813B2 (ja) 2010-08-04 2015-10-28 武田薬品工業株式会社 複素環化合物
EP3030549B8 (en) * 2013-09-12 2019-04-10 Janssen BioPharma, Inc. Pyridazinone compounds and uses thereof
CA2923075C (en) 2013-09-12 2022-07-26 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
JP6422164B2 (ja) 2013-12-26 2018-11-14 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
AU2016229147C1 (en) 2015-03-11 2021-03-25 Janssen Biopharma, Inc. Aza-pyridone compounds and uses thereof
DK3287443T3 (da) 2015-04-24 2022-02-07 Shionogi & Co 6-leddet heterocyklisk derivat og farmaceutisk sammensætning, som omfatter dette
WO2018074390A1 (ja) 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
TW202321229A (zh) 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345934A (en) 1977-03-10 1982-08-24 Rohm And Haas Company Method of producing hybrid cereal grain seeds by application of 1-aryl-1,4-dihydro-4-oxo(thio)-pyridazines
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5808082A (en) * 1996-05-08 1998-09-15 Merck & Co., Inc. Method of preparing phosphodiesterase IV inhibitors
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005061504A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof
US8299257B2 (en) * 2007-09-20 2012-10-30 Glaxo Group Limited Compounds which have activity at M1receptor and their uses in medicine

Also Published As

Publication number Publication date
DE602007011815D1 (de) 2011-02-17
JP2010510297A (ja) 2010-04-02
TW200836739A (en) 2008-09-16
CA2668196A1 (fr) 2008-06-12
FR2909090A1 (fr) 2008-05-30
ATE494290T1 (de) 2011-01-15
FR2909090B1 (fr) 2009-01-09
WO2008068424A2 (fr) 2008-06-12
KR20090092774A (ko) 2009-09-01
PE20081496A1 (es) 2009-01-04
RU2009123841A (ru) 2010-12-27
CN101541802A (zh) 2009-09-23
WO2008068424A3 (fr) 2008-07-24
IL198523A0 (en) 2010-02-17
CL2007003346A1 (es) 2008-07-04
US20090281107A1 (en) 2009-11-12
EP2094706B1 (fr) 2011-01-05
US7915258B2 (en) 2011-03-29
UY30742A1 (es) 2008-07-03
AU2007330652A1 (en) 2008-06-12
EP2094706A2 (fr) 2009-09-02
AR063898A1 (es) 2009-02-25
WO2008068424A8 (fr) 2009-07-02
BRPI0719291A2 (pt) 2014-02-25

Similar Documents

Publication Publication Date Title
MX2009005447A (es) Derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona sustituidos, su preparacion y uso de los mismos como ligandos de los receptores cb1 de canabinoides.
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
MX2008012064A (es) Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
WO2009069736A1 (ja) 含窒素化合物
WO2008012733A3 (en) Method and composition for permanently shaping hair
SG170739A1 (en) Iap bir domain binding compounds
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
WO2008126831A1 (ja) ピロール誘導体のアトロプ異性体
WO2006087476A3 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
MY153044A (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
WO2006031566A3 (en) Halogenated benzamide derivatives
HK1138262A1 (en) Novel phosphodiesterase inhibitors
WO2008136444A1 (ja) 縮合複素環誘導体
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
IN2012DN00770A (es)
MX2010001566A (es) Derivado de aminopirazolamida.
TW200609223A (en) Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives
WO2007000505A3 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
WO2007068815A3 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
IN2012DN00768A (es)
TW200734336A (en) 6-Heteroarylpyridoindolone derivatives, preparation thereof and therapeutic use thereof
MX2010007349A (es) Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas , su preparacion y su aplicacion terapeutica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal